Exposure to Alendronate is Associated with a Lower Risk of Bone Metastases in Osteoporotic Women with Early Breast Cancer

Conclusions: History of alendronate use is associated with a lower likelihood of bone metastases in postmenopausal women with early breast cancer. Oral bisphosphonate treatment could be sufficient for reducing the risk of bone metastases.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research